SpyGlass Pharma, Inc.

SGP ·Healthcare, Medical Devices, United States
Financial Statements Balance Sheet
Annual Quarterly

Balance Sheet

Line Item FY2025 FY2024 FY2023
Assets
Cash & Equivalents $96.4M $16.3M $15.8M
Accounts Receivable
Inventory
Total Current Assets $108.8M $17.4M
Property, Plant & Equipment $2.3M $2.2M
Goodwill
Intangible Assets (Excl. Goodwill)
Total Assets $115.9M $23.3M
Liabilities
Accounts Payable $2.7M $2.0M
Total Current Liabilities $8.6M $7.8M
Long-Term Debt
Total Liabilities $10.2M $11.2M
Stockholders' Equity
Retained Earnings $-104.7M $-64.9M
Total Stockholders' Equity $-98.8M $-60.5M $-33.0M